Novavax Profit Margin

The latest profit margin for NVAX is -14.73% as of March 2026. That compares with 38.14% in the prior-year period — down 138.6% year over year. That is below the Healthcare sector average of 15.29%. Investors often review this figure alongside Novavax's historical trend and sector peers before judging valuation or financial health.

Over the past year, NVAX's profit margin moved from 38.14% to -14.73% — a 138.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Novavax's valuation or profitability profile.

Against Healthcare companies, NVAX currently prints -14.73% for profit margin, while the sector average sits near 15.29%. That is roughly 196.3% below the sector mean. Large gaps often invite a closer look at Novavax's growth, margins, and balance sheet.

Profit Margin shows how effectively Novavax converts resources into returns. At -14.73%, NVAX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with 38.14% in the prior-year period — down 138.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting NVAX's profit margin (-14.73%), review year-over-year change from 38.14%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.